Subscapularis Transthoracic Versus Posterolateral Approaches in the Surgical Management of Upper Thoracic Tuberculosis: A Prospective,Randomized Controlled Study

The objective of the present study was to evaluate the clinical, radiological, and functional outcomes of a subscapularis transthoracic surgical approach and a posterolateral surgical approach with debridement, bone graft fusion, and internal fixation for the treatment of upper thoracic tuberculosis.There is currently debate over the best surgical approach for the treatment of upper thoracic tuberculosis. Traditionally, the subscapularis transthoracic approach has been preferred; however, the posterolateral approach has gained popularity in the past few years.A prospective, consecutive cohort of 43 upper thoracic tuberculosis patients with a mean age of 39 years (range: 20–52 years) was followed up for a minimum of 12 months (range: 12–60 months). Patients were randomly divided into 2 groups. Group A (n = 21) was treated by the subscapularis transthoracic approach and group B (n = 22) was treated by the posterolateral approach. All cases were evaluated for clinical, radiological, and functional outcomes. Intraoperative blood loss, operative duration, intraoperative and postoperative complications, hospital stay, the cure rate, fusion time, and the Frankel scale were used for clinical and functional evaluation, whereas the kyphosis angle was used for radiological evaluation.Grafted bones were fused by 10 months in all cases. There was no statistically significant difference between groups before surgery in terms of gender, age, segmental tuberculosis, erythrocyte sedimentation rate (ESR), Frankel scale, or Cobb''s angle (P > 0.05). The average operative duration for Group B was lower than that of Group A. There were no significant differences in intraoperative blood loss, intraoperative and postoperative complications, hospital stay, grafted bone fusion time, or cure rate between groups (P > 0.05). The Cobb''s angle correction rate for group B (68.5%) was significantly better than that of group A (30.9%). The neurological score showed significant postoperative improvement in both groups, with no significant difference between the groups.The subscapularis transthoracic approach and the posterolateral approach with debridement, bone graft fusion, and internal fixation are both sufficient and satisfactory for the surgical treatment of upper thoracic tuberculosis. However, the posterolateral approach is superior to the subscapularis transthoracic approach in terms of surgical trauma, operative time, and kyphosis correction.     

中风毒邪论与神经保护治疗的研究

中风毒邪论是一种与传统中医中风病理有所不同的理论 ,在中风毒邪论指导下形成解毒通络方是较为理想的神经保护剂 ,可解决目前神经保护治疗的主要障碍 ,有望成为提高中医治疗中风急性期疗效的关键     

低温保存同种心脏瓣膜活性及临床应用的研究

取正常成人心脏瓣膜３６个，置于低浓度广谱抗生素的营养液（ＲＰ－ＭＩ１６４０细胞培养液）中灭菌４８ｈ，－８０℃冰箱初冻，置于液氮中长期保存。灭菌前后瓣膜细菌培养阴性率分别为９４．３％和１００％，解冻后经光镜、电镜检查证实瓣组织细胞结构正常，组织培养葡萄糖消耗率测定示瓣组织存活良好。临床同种心脏瓣膜原位移植３例，随访６～３０个月，瓣功能良好     

微波凝固联合黏膜下氟尿嘧啶注射治疗早期低位直肠癌

目的探讨微波凝固联合黏膜下氟尿嘧啶（5-Fu）注射治疗早期低位直肠癌的适应证和疗效。方法1996年1月～2002年12月对9例早期低位直肠癌采用微波凝固联合黏膜下5-Fu注射，微波治疗后用含5．Fu1．0g的生理盐水100～200ml保留灌肠，1次／d，连续3d，随访其疗效。结果3例微波治疗前CEA增高，微波治疗后CEA下降至正常。术中、术后无出血等并发症。随访至2006年1月，9例全部存活。l例生存3年5个月；1例生存3年8个月；1例1年4个月后肿瘤复发，行Miles手术至今又生存2年9个月；6例生存5年以上，其中1例5年1个月，1例6年3个月，l例6年8个月，1例7年6个月，2例9年。结论微波凝固联合黏膜下5-Fu注射治疗早期低位直肠癌适应于早期、距肛缘7cm以下、肿块型、肿瘤直径0．5～3．0cm或肿瘤〈直肠周径的1／3、病理类型为高分化肿瘤、且患者强烈要求保肛的直肠癌。该方法具有创伤小、费用低和疗效满意等特点。     

“津血同源”“肾为唾”的研究

以23例肾功能不全与20例肾功正常患者的唾液尿素氮、钠、钾、舌面pH值和血液的相应生化检查作对照。结果唾液尿素氮、钾与血尿素氮、钾成正相关性。证实了中医“津血同源”“肾为唾”的理论。     

吸入一氧化氮对心瓣膜置换术后肺动脉高压患者血流动力学的影响

目的：观察吸入一氧化氮（ＮＯ）对心瓣膜置换术后肺动脉高压患者血流动力学的影响。方法：选择９例心瓣膜置换术后伴肺动脉高压的病人，吸入ＮＯ０．００３％，观察三个时象点：吸入ＮＯ前；开始吸入ＮＯ后１５分钟；停止吸入ＮＯ后１５分钟。结果：吸入ＮＯ能显著降低肺动脉压和肺循环阻力指数（Ｐ＜０．０１），停止吸入ＮＯ１５分钟后，肺动脉压和肺循环阻力指数恢复到原有水平。在整个观察过程中，心率、平均动脉压、中心静脉压、肺动脉楔压、体循环阻力指数和心脏指数均无显著变化（Ｐ＞０．０５）。结论：吸入ＮＯ具有选择性肺血管扩张作用，是治疗心瓣膜置换术后肺动脉高压的较理想药物。     

人β-防御素3基因在COS-7细胞中的表达

目的：构建人β—防御素3(hBD3)的真核表达载体，建立稳定表达hBD3的细胞株。方法：用EcoR Ⅰ酶切合有hBD3全长基因的pGEM-hBD3重组质粒，获得其编码区全长序列，将其连接入EcoR Ⅰ预处理过的pcDNA3中。转化大肠杆菌，酶切鉴定筛选出插入方向正确的转化子。采用脂质体转染法将重组pcDNA3-hBD3真核表达载体导入COS-7细胞，用G418进行抗性筛选，用RT-PCR和Western印迹检测目的基因hBD3的mRNA和蛋白表达水平。结果与结论：构建的pcDNA3-hBD3真核表达载体转染COS-7细胞后可稳定表达hBD3的mRNA和蛋白，且蛋白主要以分泌形式存在于培养上清中。